PPARG and metabolic dysfunction-associated steatohepatitis: High insulin levels accelerate the development of NAFLD through a PPARγ-dependent pathway.387 PPARγ agonists, thiazolidinediones, have been used as insulin sensitizers in diabetic patients.388 PPARδ agonists improved the pathological manifestations of nonalcoholic steatohepatitis (NASH) without affecting body weight.